ReviewEpilepsia open2022
Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe.
Review in Epilepsia open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Recommendations for the community-based management of prolonged convulsive seizures in children in Europe.BMC pediatrics · 2026Guideline
- Dravet syndrome: A systematic literature review of the illness burden.Epilepsia open · 2023Pooled it
- Crisis epilépticas en niños con síndrome de Dravet en condiciones de calor extremo: estudio cualitativo de la perspectiva de los progenitores.Developmental medicine and child neurology · 2026Article
- Seizures in children with Dravet syndrome in extreme heat: A qualitative study of parental perspectives.Developmental medicine and child neurology · 2026Article
- Efficacy of stiripentol, fenfluramine, and their combination on clinical outcomes in Dravet syndrome: A preliminary report.Epilepsia open · 2026Article
- From first seizure to specific antiseizure medication in Dravet syndrome: Quantifying delays in the DS'coverED study.Epilepsia open · 2026Article
- Optimizing polytherapy management for Dravet syndrome in the United States: A National Expert Consensus.Epilepsia open · 2026Article
- [Associations Between Genetic Causes of Psychiatric Disorders and Rare Monogenic Epilepsies].Der Nervenarzt · 2026Review
- AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet syndrome.Molecular therapy. Nucleic acids · 2026Article
- Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach.Epilepsia open · 2026Article
- Fenfluramine-associated pulmonary hypertension: a study of adverse events reporting system FAERS.ERJ open research · 2026Article
- The Difficult Journey of a Child with Dravet Syndrome: Perspectives from a Parent and the Neuropaediatrician.Neurology and therapy · 2025Article
- Variability vs. phenotype: Multimodal analysis of Dravet syndrome brain organoids powered by deep learning.iScience · 2025Article
- Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome.Epilepsia open · 2025Article
- Review
- Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome.Epilepsia · 2025Article
- A research roadmap for SCN8A-related disorders: addressing knowledge gaps and aligning research priorities across stakeholders.Orphanet journal of rare diseases · 2025Article
- Comparative assessment of artificial intelligence chatbots' performance in responding to healthcare professionals' and caregivers' questions about Dravet syndrome.Epilepsia open · 2025Article
- Communicating a diagnosis of Dravet syndrome to parents/caregivers: An international Delphi consensus.Epilepsia open · 2025Article
- Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome.Brain, behavior, & immunity - health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dravet syndrome (DS) is a severe, rare, and complex developmental and epileptic encephalopathy affecting 1 in 16 000 live births and characterized by a drug-resistant epilepsy, cognitive, psychomotor, and language impairment, and behavioral disorders. Evidence suggests that optimal treatment of seizures in DS may improve outcomes, even though neurodevelopmental impairments are the likely result of both the underlying genetic variant and the epilepsy. We present an updated guideline for DS diagnosis and treatment, taking into consideration care of the adult patient and nonpharmaceutical therapeutic options for this disease. This up-to-date guideline, which is based on an extensive review of the literature and culminates with a new treatment algorithm for DS, is a European consensus developed through a survey involving 29 European clinical experts in DS. This guideline will serve professionals in their clinical practice and, as a consequence, will benefit DS patients and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.